HIV Drug Development--Emerging Technologies

Table of Contents

1. Executive Summary

• 1. Introduction
  • 1. Introduction to HIV
  • 2. Prevalence
• 2. Scope and Methodology
  • 1. Scope
  • 2. Methodology

2. Technology and Applications View Point

• 1. Technology Primer
  • 1. Drugs
  • 2. Vaccines
  • 3. Microbicides
  • 4. The Red Ribbon Project
• 2. Trends and Important Clinical Trials
  • 1. In Development
  • 2. Global Scenario
  • 3. Important Clinical Trials

3. Technology Adoption Factor Analysis

• 1. Drivers and Challenges
  • 1. Drivers
  • 2. Challenges
• 2. Regulatory Hurdles and Funding
  • 1. Regulatory Hurdles
  • 2. Funding

4. Technological Advancements--Drugs

• 1. Technological Advancements--Companies
  • 1. Viral Entry Inhibitor-Based Monoclonal Antibody for HIV Treatment--USA
  • 2. Novel Entry Inhibitor-Based Drug for Protecting Healthy Cells from HIV Infection--Canada
  • 3. Innovative Entry Inhibitor-Based Drug Pipeline as HIV Therapeutics--USA
  • 4. Nucleoside Reverse Transcriptase Inhibitor Drug-Based Therapy for Prevention of HIV Infection--USA
  • 5. Drug Preventing the Action of Enzyme Required for Replication--USA
  • 6. Entry Inhibitor-Based Drug for Prevention of HIV Infection--USA
  • 7. Reverse Transcriptase Enzyme Inhibitor for Prevention of Fresh Infection of Cells--USA
  • 8. Telomerase-Based Drug for Enhancing Antiviral Activity Targeting HIV Infection--China
• 2. Technological Advancements--Research Institutions
  • 1. Dynamic Host-Viral Interactions to Aid in Drug Development
  • 2. Scientists Reveal the Molecule Involved in HIV Integration with Host Genetic Component

5. Technological Advancements--Vaccines and Microbicides

• 1. Technological Advancements in Companies--Vaccines
  • 1. AdVac-Based Vaccines to Tackle HIV--Netherlands
  • 2. DNA-Based Vaccine for HIV--U.S.
  • 3. Monoclonals for Blocking HIV--U.S.
  • 4. Plant-Based HIV vaccines--U.S.
  • 5. Therapore Technology-Based HIV Vaccine--U.S.
  • 6. Dendritic Cell Technology for AIDS Vaccine--United Kingdom
• 2. Technological Advanvements in Companies--Mictrobicides
  • 1. Gel Based Microbicide for the Prevention of HIV Infection--Canada
  • 2. Microbicide Based Gel Tackling HIV Infection--Australia
  • 3. Microbicide-Based Gel for Counter-Attacking HIV Infection--U.S.
  • 4. Oligonucleotide-Based Microbicide for HIV Prevention--U.S.
• 3. Research Institutions
  • 1. Vaccine to Tackle HIV Using Genetically Modified Tobacco--UK
  • 2. Retroviral-Based Approach for Interfering with HIV Replication--India
  • 3. Liposome-Based Adjuvant for Development of Vaccines--India
  • 4. Adenovector-Based Vaccine to Target HIV--U.S.
  • 5. Novel Targets for Antiviral Approach against HIV--India
  • 6. Plant-Based Vaccine for HIV--Russia

6. Key Patents; Contacts; and Glossary

• 1. Key Patents
  • 1. Patents--Drugs and Developments
  • 2. Patents--Vaccines
• 2. Contacts and Glossary
  • 1. Contacts
  • 2. Glossary

7. Frost & Sullivan 2006 Science & Technology Awards

• 1. Technology Innovation Award
  • 1. Award Description
  • 2. Award Recipient
• 2. Excellence in Technology Award
  • 1. Award Description.
  • 2. Award Recipient
• 3. Excellence in Research Award
  • 1. Award Description
  • 2. Award Recipient

8. Decision Support Database

• 1. Database Tables
  • 1. Number of Biotech Companies (1999-2006)
  • 2. Government Investment in Biotech R&D (1999-2006)
  • 3. Private Investment in Biotech (1999-2006)
  • 4. HIV Prevalence (1999-2006)
  • 5. AIDS Mortality (1999-2006)